Relay Therapeutics rallies on initial trial data for rare disease drug

Relay Therapeutics (NASDAQ:RLAY) announced positive initial data from an ongoing mid-stage clinical trial evaluating its precision medicine candidate, zovegalisib, in patients with rare genetic vascular anomalies.

The Cambridge, Massachusetts-based biotechnology firm disclosed results from the Phase 2 ReInspire trial, which tests the allosteric drug in patients with malformations driven by mutations in the PIK3CA gene.

These rare disorders cause abnormal development of blood vessels, lymphatic vessels, and surrounding tissues, and currently have limited targeted treatment options.

Among 20 response-evaluable adult and adolescent patients participating in the Part 1 dose-randomization portion of the study, 60% achieved a volumetric lesion response at the earliest structured milestone of 12 weeks.

That response rate climbed to 65% following the formal data cut-off period, pointing toward deeper therapeutic responses over extended exposure.

Symptom tracking also indicated broad clinical benefit across the small patient cohort.

Interim outcomes revealed that 89% of investigators and 79% of patients reported measurable clinical improvements at week 12.

Crucially for a disease group requiring prolonged therapeutic management, the interim safety and tolerability profile supported long-term, chronic dosing.

Relay stated that the observed safety metrics confirm a viable therapeutic window at optimized regimens, with no patients discontinuing treatment due to adverse side effects.

Based on the preliminary findings, the company has opened adult and adolescent expansion cohorts evaluating optimized dosing schedules at 400 milligrams once daily and 300 milligrams twice daily.

Pediatric dose-finding cohorts remain ongoing to establish proper therapeutic limits for younger patient populations.